Table 2 Stage progression rates and incidence rates of stage progression of NF1 from 2009 to 2012 by age and clinical stage at registration in 2008
No. of cases (A) | No. of cases with renewal claim (B) | No. of cases with no renewal claims | Renewal rate (B/A) | No. of cases with stage progression (C) | No. of cases with dermatological progression | No. of cases with neurological progression | No. of cases with bone progression | Person-years (D) a) | Stage progression rate (C/A) b) | Incidence rate per 100 person-years (C/D) | |
|---|---|---|---|---|---|---|---|---|---|---|---|
Total | 342 | 205 | 137 | 60% | 30 | 13 | 16 | 8 | 245.0 | 19% | 12.2 |
Age group | |||||||||||
0–19 yrs | 74 | 47 | 27 | 64% | 7 | 1 | 4 | 4 | 28.0 | 26% | 25.0 |
20–39 yrs | 109 | 65 | 44 | 60% | 10 | 6 | 7 | 1 | 89.0 | 19% | 11.2 |
40–59 yrs | 89 | 53 | 36 | 60% | 6 | 4 | 2 | 1 | 77.5 | 12% | 7.7 |
> 60 yrs | 70 | 40 | 30 | 57% | 7 | 2 | 3 | 2 | 50.5 | 21% | 13.9 |
Clinical stage | |||||||||||
Stage 1, 2 | 57 | 19 | 38 | 33% | 10 | 6 | 7 | 2 | 63.0 | 18% | 15.9 |
Stage 3, 4 | 105 | 67 | 38 | 64% | 20 | 7 | 9 | 6 | 182.0 | 19% | 11.0 |
Stage 5 | 180 | 119 | 61 | 66% | – | – | |||||
Age×clinical stage | |||||||||||
0–19 yrs | |||||||||||
Stage 1, 2 | 18 | 7 | 11 | 39% | 3 | 0 | 2 | 1 | 20.0 | 17% | 15.0 |
Stage 3, 4 | 9 | 5 | 4 | 56% | 4 | 1 | 2 | 3 | 8.0 | 44% | 50.0 |
Stage 5 | 47 | 35 | 12 | 74% | – | – | |||||
20–39 yrs | |||||||||||
Stage 1, 2 | 24 | 9 | 15 | 38% | 6 | 5 | 4 | 1 | 26.5 | 25% | 22.6 |
Stage 3, 4 | 29 | 20 | 9 | 69% | 4 | 1 | 3 | 0 | 62.5 | 14% | 6.4 |
Stage 5 | 56 | 36 | 20 | 64% | – | – | |||||
40–59 yrs | |||||||||||
Stage 1, 2 | 8 | 2 | 6 | 25% | 1 | 1 | 1 | 0 | 10.5 | 13% | 9.5 |
Stage 3, 4 | 41 | 23 | 18 | 56% | 5 | 3 | 1 | 1 | 67.0 | 12% | 7.5 |
Stage 5 | 40 | 28 | 12 | 70% | – | – | |||||
> 60 yrs | |||||||||||
Stage 1, 2 | 7 | 1 | 6 | 14% | 0 | – | – | – | 6.0 | 0% | 0.0 |
Stage 3, 4 | 26 | 19 | 7 | 73% | 7 | 2 | 3 | 2 | 44.5 | 27% | 15.7 |
Stage 5 | 37 | 20 | 17 | 54% | – | – | |||||